Drug Type Chemical drugs |
Synonyms |
Target |
Mechanism Nicotinic receptors agonists |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Monument Therapeutics Ltd.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cognitive Dysfunction | Preclinical | GB | Monument Therapeutics Ltd.Startup | 30 Jan 2022 |
Cognitive Dysfunction | Preclinical | GB | 30 Jan 2022 | |
Schizophrenia | Preclinical | GB | - | |
Schizophrenia | Preclinical | GB | Monument Therapeutics Ltd.Startup | - |
Autistic Disorder | Discovery | GB | Monument Therapeutics Ltd.Startup | - |